Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals

Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals

Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to generic companies to mass produce the DAAs sofosbuv...

Full description

Bibliographic Details
Main Authors: Andrew Hill, Loai Tahat, Mohammed Khalil Mohammed, R.abab Fayez Tayyem, Giten Khwairakpam, Sanjay Nath, James Freeman, Ismahane Benbitour, Sherine Helmy
Format: Article
Language:English
Published: Elsevier 2018-04-01
Series:Journal of Virus Eradication
Subjects:
hepatitis C, HCV, direct-acting antivirals, bioequivalence, generics, sofosbuvir, daclatasvir
Online Access:http://www.sciencedirect.com/science/article/pii/S2055664020302570

Internet

http://www.sciencedirect.com/science/article/pii/S2055664020302570

Similar Items